Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE

Haemonetics Corp shares on the New York Stock Exchange continued to trade below recent highs on 06/01/2026, keeping the US medical technology group in focus for investors after its latest quarterly update and price fluctuations in the healthcare sector.

Haemonetics Corp shares on the New York Stock Exchange were quoted below their recent highs on 06/01/2026, keeping the United States-based medical technology company on the radar of healthcare investors after a period of price consolidation following its latest quarterly report, according to data from Investing.com as of 06/01/2026.

The stock continues to trade in US dollars under the ticker HAE on NYSE, anchoring it in the United States equity market alongside other mid-cap healthcare names, while trading data on 06/01/2026 from Investing.com indicate that the share price remains well below the 52-week peak reached earlier in the year.

The trading action comes in the wake of the company’s most recent earnings release for the fourth quarter and full fiscal year 2025, which Haemonetics filed with the U.S. Securities and Exchange Commission and published on its investor relations pages in May 2025, detailing revenue, margin trends and cash flow metrics that continue to shape investor views on the stock.

According to the company’s May 2025 earnings release and related SEC filings, Haemonetics reported year-on-year growth in key segments such as plasma, hospital and blood center solutions, with the United States remaining its core market, and investors have been digesting these figures against a backdrop of broader volatility in the healthcare equipment and supplies segment.

The stock’s positioning on NYSE also means that Haemonetics is influenced by U.S. macroeconomic data, interest-rate expectations and sector flows affecting healthcare and medical device companies, with market participants closely watching trading volumes and intraday moves around catalyst dates such as earnings, regulatory announcements and product updates.

As of 06/01/2026, the shares continue to reflect the market’s assimilation of the fiscal 2025 numbers, including revenue performance, operating margin developments and guidance commentary, while short-term traders monitor price reactions in comparison to other U.S.-listed medtech companies active in blood management and hospital solutions.

Some investors also follow trading in Haemonetics shares on German venues such as Tradegate for additional liquidity in euros, where indicative quotes on 06/01/2026 show the stock mirroring the New York price action once currency effects are taken into account.

At the same time, valuation-oriented market participants compare the current NYSE price level with fundamental indicators such as earnings power and cash generation disclosed in the May 2025 results, assessing how the ongoing pullback fits into the company’s longer-term operating trajectory.

The recent share price performance thus encapsulates a combination of company-specific data points from the most recent fiscal year and broader sector dynamics in U.S. healthcare equipment, leaving Haemonetics in focus for investors seeking exposure to medical technology names that specialize in blood management solutions.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Haemonetics Corp
• Sector/industry: Medical technology, blood management solutions
• Headquarters/country: Boston, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Plasma collection systems, hospital hemostasis management, blood center solutions and related disposables
• Home exchange/listing venue: New York Stock Exchange (HAE)
• Trading currency: USD

Haemonetics Corp: core business model

Haemonetics generates its business by supplying specialized blood and plasma collection devices, software and consumables to hospitals, plasma centers and blood collection organizations, with recurring revenue largely tied to the ongoing use of its installed base and procedure volumes.

What banks and research houses say about Haemonetics Corp

No verified analyst coverage was identified at the time of publication.

Conclusion

The ongoing share price consolidation of Haemonetics Corp on the New York Stock Exchange on 06/01/2026 reflects the market’s continued assessment of the company’s fiscal 2025 performance and outlook in the context of broader U.S. healthcare equipment trends.

With its focus on blood and plasma management technology and a significant presence in the United States medical system, the stock remains closely watched whenever new financial data points and sector news emerge, even as readily verifiable analyst commentary is limited at the time of publication.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.